| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.9M | +20.4% |
| R&D Expense | $136.8M | +117.3% |
| SG&A Expense | $26.4M | +53.8% |
| Operating Income | -$160.4M | -106.2% |
| Income Tax | $0 | — |
| Net Income | -$143.4M | -128.4% |
| EPS (Basic) | -$2.66 | +52.3% |
| EPS (Diluted) | -$2.66 | +52.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $101.6M | -68.8% |
| Short-term Investments | $239.9M | +66.0% |
| Accounts Receivable | $668K | +9.0% |
| Current Assets | $351.8M | -26.6% |
| Total Assets | $353.8M | -26.6% |
| Current Liabilities | $13.5M | +25.3% |
| Total Liabilities | $14.0M | +18.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$133.3M | -125.2% |
| Capital Expenditures | $165K | -67.7% |
| Investing Cash Flow | -$93.5M | -57.1% |
| Financing Cash Flow | $2.4M | -99.4% |
| Free Cash Flow | -$133.4M | -123.6% |
| Stockholders' Equity |
| $339.8M |
| -27.7% |